Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations.
作者信息
Li Pengfei, de Vries Annemarie C, Kamar Nassim, Peppelenbosch Maikel P, Pan Qiuwei
机构信息
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, NL-3015 Rotterdam, Netherlands.
Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease, Paul Sabatier University, Toulouse, France.
出版信息
Lancet Microbe. 2022 May;3(5):e325-e326. doi: 10.1016/S2666-5247(22)00061-1. Epub 2022 Mar 15.
Abstract
摘要
相似文献
1
Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations.监测和管理免疫功能低下人群中新冠病毒的进化
Lancet Microbe. 2022 May;3(5):e325-e326. doi: 10.1016/S2666-5247(22)00061-1. Epub 2022 Mar 15.
2
SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients.免疫功能低下患者中SARS-CoV-2的进化与免疫逃逸
N Engl J Med. 2022 Jun 23;386(25):2436-2438. doi: 10.1056/NEJMc2202861. Epub 2022 Jun 8.
3
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.长达一年的 COVID-19 感染揭示了 B 细胞耗竭患者体内 SARS-CoV-2 的宿主内进化。
J Infect Dis. 2022 Apr 1;225(7):1118-1123. doi: 10.1093/infdis/jiab622.
4
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection.对一名患有长期新冠病毒2型（SARS-CoV-2）感染的免疫功能低下患者的病毒免疫学评估。
Emerg Microbes Infect. 2022 Dec;11(1):786-789. doi: 10.1080/22221751.2022.2045877.
5
Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性单克隆抗体治疗免疫功能低下宿主的持续性2019冠状病毒病（COVID-19）
Clin Infect Dis. 2022 May 3;74(9):1706-1707. doi: 10.1093/cid/ciab868.
6
SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.免疫功能低下患者接受抗体单药治疗后的 SARS-CoV-2 变异株。
Emerg Infect Dis. 2021 Oct;27(10):2725-2728. doi: 10.3201/eid2710.211509. Epub 2021 Aug 5.
7
SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.免疫功能低下的新冠肺炎患者中的新冠病毒2变体：根本原因及未来方向
Transfus Clin Biol. 2022 May;29(2):161-163. doi: 10.1016/j.tracli.2021.12.006. Epub 2021 Dec 29.
8
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts.免疫功能低下宿主体内 SARS-CoV-2 刺突突变的长期感染中出现。
Microbiol Spectr. 2022 Jun 29;10(3):e0079122. doi: 10.1128/spectrum.00791-22. Epub 2022 May 11.
9
Boosting SARS-CoV-2 immunity in immunocompromised individuals.增强免疫功能低下个体对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫力。
Genes Immun. 2024 Apr;25(2):168-169. doi: 10.1038/s41435-023-00219-6. Epub 2023 Dec 19.
10
Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.两名免疫功能低下患者的 SARS-CoV-2 病毒持续排出：病例报告
BMC Infect Dis. 2021 Aug 3;21(1):743. doi: 10.1186/s12879-021-06429-5.
引用本文的文献
1
An In-Depth Characterization of SARS-CoV-2 Omicron Lineages and Clinical Presentation in Adult Population Distinguished by Immune Status.SARS-CoV-2奥密克戎谱系的深入特征分析及按免疫状态区分的成年人群临床表现
Viruses. 2025 Apr 8;17(4):540. doi: 10.3390/v17040540.
2
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.莫努匹拉韦和奈玛特韦对重症COVID-19模型中SARS-CoV-2基因组多样性的影响。
Microbiol Spectr. 2025 May 6;13(5):e0182924. doi: 10.1128/spectrum.01829-24. Epub 2025 Mar 25.
3
Recombinant SARS-CoV-2 Delta/Omicron BA.5 emerging in an immunocompromised long-term infected COVID-19 patient.免疫功能低下的新冠长期感染者中出现的重组 SARS-CoV-2 Delta/Omicron BA.5。
Sci Rep. 2024 Oct 28;14(1):25790. doi: 10.1038/s41598-024-75241-3.
4
Preamplification-free viral RNA diagnostics with single-nucleotide resolution using MARVE, an origami paper-based colorimetric nucleic acid test.使用 MARVE（一种折纸纸基比色核酸检测），实现无需预扩增的单核苷酸分辨率病毒 RNA 诊断。
Nat Protoc. 2024 Nov;19(11):3426-3455. doi: 10.1038/s41596-024-01022-x. Epub 2024 Jul 18.
5
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.血液系统疾病患者和细胞治疗接受者的奥密克戎SARS-CoV-2感染管理及结局
Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024.
6
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.莫努匹韦和奈玛特韦对重症COVID-19模型中SARS-CoV-2基因组多样性的影响。
bioRxiv. 2024 Dec 20:2024.02.27.582110. doi: 10.1101/2024.02.27.582110.
7
Using big sequencing data to identify chronic SARS-Coronavirus-2 infections.利用大测序数据识别慢性严重急性呼吸系统综合征冠状病毒 2 感染。
Nat Commun. 2024 Jan 20;15(1):648. doi: 10.1038/s41467-024-44803-4.
8
Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan.日本爱知县单中心回顾性研究：瑞德西韦联合单克隆抗体与瑞德西韦单药治疗轻中度 COVID-19 合并免疫抑制患者的比较有效性和安全性的真实世界经验。
Viruses. 2023 Sep 19;15(9):1952. doi: 10.3390/v15091952.
9
Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.吲哚美辛通过同时抑制病毒复制和炎症反应来对抗全冠状病毒感染。
iScience. 2023 Aug 16;26(9):107631. doi: 10.1016/j.isci.2023.107631. eCollection 2023 Sep 15.
10
Within-Host Evolution of SARS-CoV-2 in a B-Cell Depleted Patient With Successful Treatment.B 细胞耗竭患者成功治疗后 SARS-CoV-2 的体内进化。
J Korean Med Sci. 2023 Jun 5;38(22):e175. doi: 10.3346/jkms.2023.38.e175.
本文引用的文献
1
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape.在晚期 HIV 疾病中，SARS-CoV-2 持续感染会导致广泛的免疫逃逸。
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5. doi: 10.1016/j.chom.2022.01.005. Epub 2022 Jan 14.
2
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination.严重急性呼吸综合征冠状病毒2型奥密克戎变种对莫努匹拉韦、奈玛特韦及二者联用高度敏感。
Cell Res. 2022 Mar;32(3):322-324. doi: 10.1038/s41422-022-00618-w. Epub 2022 Jan 20.
3
Omicron overpowers key COVID antibody treatments in early tests.在早期测试中，奥密克戎毒株使主要的新冠病毒抗体疗法失效。
Nature. 2021 Dec 21. doi: 10.1038/d41586-021-03829-0.
4
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体：新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
5
Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials.持续性严重急性呼吸综合征冠状病毒2感染：急需获得治疗和开展试验。
Lancet Infect Dis. 2021 Oct;21(10):1345-1347. doi: 10.1016/S1473-3099(21)00464-3. Epub 2021 Aug 16.
6
Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.两名免疫功能低下患者的 SARS-CoV-2 病毒持续排出：病例报告
BMC Infect Dis. 2021 Aug 3;21(1):743. doi: 10.1186/s12879-021-06429-5.
7
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
8
Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants.研究人员将严重免疫抑制与慢性新冠病毒感染及病毒变体联系起来。
JAMA. 2021 May 25;325(20):2033-2035. doi: 10.1001/jama.2021.7212.
9
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
10
Whole-Genome Next-Generation Sequencing to Study Within-Host Evolution of Norovirus (NoV) Among Immunocompromised Patients With Chronic NoV Infection.全基因组下一代测序研究免疫功能低下的慢性诺如病毒（NoV）感染患者体内诺如病毒（NoV）的宿主内进化。
J Infect Dis. 2017 Dec 19;216(12):1513-1524. doi: 10.1093/infdis/jix520.
Zotero 插件